Rare and orphan diseases focused Amryt Pharma said the Federal Drug Administration had designated the investigation of a treatment for epidermolysis bullosa as a fast-track development program. The company said the FDA had recognised epidermolysis bullosa (EB) as a serious diseases and that there were no FDA-approved treatments for the condition. The US regulator had also noted that Amryt had generated preliminary clinical data from an ongoing Phase 3 trial, which supported continued study. 'Receiving a fast track designation from the FDA represents another significant step in the progress of our lead development asset - AP101 - as a potential treatment for the wound related complications of EB, a rare and life limiting condition,' chief executive Joe Wiley said. 'This designation, alongside the other significant efforts of our team globally, drives our continued progress and brings us closer to realising our vision of becoming a global leader in rare and orphan diseases.' At 2:25pm: (LON:AMYT) Amryt Pharma share price was +1.5p at 132.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.